Shaping the Future with Pompe Patients - Astellas Pharma
  Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B - Fierce Biotech
  Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PR Newswire
  Astellas and Hoyng ROKH successfully defend Xtandi in the Netherlands - JUVE Patent
  Astellas Pharma Inc.'s (TSE:4503) P/E Is On The Mark - simplywall.st
  Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
  Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug - MedCity News
  Astellas and Pfizer’s XTANDIâ„¢ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Pfizer